secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001654954-23-010765
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA files FDA De Novo for TAEUS liver system; Q2 loss $2.6M, cash $4.8M
-------------------------------------------------------------------------

- Submitted De Novo request to FDA for TAEUS liver fat assessment system; clinical data showed 90% sensitivity and correlation r=0.78 vs MRI-PDFF.
- Q2 2023 net loss $2.6M ($0.43/share) vs $3.6M ($1.17) in Q2 2022; operating expenses fell to $3.0M from $3.6M.
- Cash and equivalents $4.8M at June 30; $4.7M net raised in May 2023 public offering to extend runway through key 2023 milestones.
- IP portfolio expanded to 64 issued patents globally; four new patents issued in Q2 (one US, three China).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/0001654954-23-010765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423010765/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer